https://wiki.tiffa.net/w/index.php?action=history&feed=atom&title=Translations%3ASGLT2_inhibitor%2F23%2Fja 2026-10-12T04:35:42Z Revision history for this page on the wiki MediaWiki 1.43.0 https://wiki.tiffa.net/w/index.php?title=Translations:SGLT2_inhibitor/23/ja&diff=114116&oldid=prev 2024-02-12T12:14:09Z

<p></p> <table style="background-color: #fff; color: #202122;" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="en"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 21:14, 12 February 2024</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l2">Line 2:</td> <td colspan="2" class="diff-lineno">Line 2:</td></tr> <tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|+ 表2: 様々なSGLT-2阻害剤の薬物動態パラメータ</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|+ 表2: 様々なSGLT-2阻害剤の薬物動態パラメータ</div></td></tr> <tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td></tr> <tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>! 薬物名 !! 生物学的利用能 !! タンパク質結合 !! <del style="font-weight: bold; text-decoration: none;">最大（時間） </del>!! t1/2 (hours) !! Cmax !! SGLT1に対するSGLT2選択性</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>! 薬物名 !! 生物学的利用能 !! タンパク質結合 !! <ins style="font-weight: bold; text-decoration: none;">tmax（時間） </ins>!! t1/2 (hours) !! Cmax !! SGLT1に対するSGLT2選択性</div></td></tr> <tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>|-</div></td></tr> <tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| [[Canagliflozin/ja]] || 65% (300&amp;nbsp;mg dose) || 99% || 1–2 || 10.6 (100&amp;nbsp;mg dose); 13.1 (300&amp;nbsp;mg dose) || 1096&amp;nbsp;ng/mL (100&amp;nbsp;mg dose); 3480&amp;nbsp;ng/mL (300&amp;nbsp;mg dose) || 250 fold</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>| [[Canagliflozin/ja]] || 65% (300&amp;nbsp;mg dose) || 99% || 1–2 || 10.6 (100&amp;nbsp;mg dose); 13.1 (300&amp;nbsp;mg dose) || 1096&amp;nbsp;ng/mL (100&amp;nbsp;mg dose); 3480&amp;nbsp;ng/mL (300&amp;nbsp;mg dose) || 250 fold</div></td></tr> </table>

Fire https://wiki.tiffa.net/w/index.php?title=Translations:SGLT2_inhibitor/23/ja&diff=114107&oldid=prev 2024-02-12T12:12:01Z

<p>Created page with &quot;{| class=&quot;wikitable&quot; |+ 表2: 様々なSGLT-2阻害剤の薬物動態パラメータ |- ! 薬物名 !! 生物学的利用能 !! タンパク質結合 !! 最大（時間） !! t1/2 (hours) !! Cmax !! SGLT1に対するSGLT2選択性 |- | <a href="/w/index.php?title=Canagliflozin/ja&amp;action=edit&amp;redlink=1" class="new" title="Canagliflozin/ja (page does not exist)">Canagliflozin/ja</a> || 65% (300 mg dose) || 99% || 1–2 || 10.6 (100 mg dose); 13.1 (300 mg dose) || 1096 ng/mL (100 mg dose); 3480 ng/mL (300 mg dose) || 250 fold |- | <a href="/w/index.php?title=Dapagliflozin/ja&amp;action=edit&amp;redlink=1" class="new" title="Dapagliflozin/ja (page does not exist)">Dapagliflozin/ja</a> || 78% || 91...&quot;</p> <p><b>New page</b></p><div>{| class=&quot;wikitable&quot;<br /> |+ 表2: 様々なSGLT-2阻害剤の薬物動態パラメータ<br /> |-<br /> ! 薬物名 !! 生物学的利用能 !! タンパク質結合 !! 最大（時間） !! t1/2 (hours) !! Cmax !! SGLT1に対するSGLT2選択性<br /> |-<br /> | [[Canagliflozin/ja]] || 65% (300&amp;nbsp;mg dose) || 99% || 1–2 || 10.6 (100&amp;nbsp;mg dose); 13.1 (300&amp;nbsp;mg dose) || 1096&amp;nbsp;ng/mL (100&amp;nbsp;mg dose); 3480&amp;nbsp;ng/mL (300&amp;nbsp;mg dose) || 250 fold<br /> |-<br /> | [[Dapagliflozin/ja]] || 78% || 91% || 1–1.5 || 12.9 || 79.6&amp;nbsp;ng/mL (5&amp;nbsp;mg dose); 165.0&amp;nbsp;ng/mL (10&amp;nbsp;mg dose) || 1200 fold<br /> |-<br /> | [[Empagliflozin/ja]] || 90–97% (mice); 89% (dogs); 31% (rats) || 86.20% || 1.5 || 13.2 (10&amp;nbsp;mg dose); 13.3h (25&amp;nbsp;mg dose) || 259nmol/L (10&amp;nbsp;mg dose); 687nmol/L (25&amp;nbsp;mg dose) || 2500 fold<br /> |-<br /> | [[Ertugliflozin/ja]] || 70-90% || 95% || 0.5-1.5 || 11-17 ||268&amp;nbsp;ng/mL (15&amp;nbsp;mg dose) || 2000 fold<br /> |-<br /> | [[Ipragliflozin/ja]] (50&amp;nbsp;mg) || 90% || 96.30% || 1 || 15–16 (50&amp;nbsp;mg dose) || 975&amp;nbsp;ng/mL || 360 fold<br /> |-<br /> | [[Luseogliflozin/ja]] || 35.3% (male rats); 58.2% (female rats); 92.7% (male dogs) || 96.0–96.3% || 0.625±0.354 || 9.24±0.928 || 119±27.0&amp;nbsp;ng/mL || 1650 fold<br /> |-</div>

Fire